Articles tagged with: Revlimid

News»

[ by and | Jan 9, 2012 3:32 pm | Comments Off ]
Revlimid-Dexamethasone Combination Delays Disease Progression In Patients With Smoldering Multiple Myeloma (ASH 2011)

The most recent results of a Spanish Phase 3 clinical trial indicate that Revlimid in combination with dexamethasone delays disease progression in smoldering multiple myeloma patients who have a high risk of developing symptomatic disease.

Specifically, the results showed that high-risk smoldering multiple myeloma patients who received Revlimid plus dexamethasone had a longer time to disease progression and better overall survival than patients who did not receive treatment.

However, the Spanish researchers acknowledged that these results should be confirmed by long-term follow-up data, especially regarding the difference in overall survival. …

Read the full story »

News»

[ by | Dec 28, 2011 4:50 pm | 2 Comments ]
ASH 2011 – The Meeting’s Myeloma-Related “Hidden Gem”

What were the myeloma-related "hidden gems" of the recent American Society of Hematology (ASH) annual meeting, which ended two weeks ago?

The Beacon asked exactly this question of its Medical Advisors -- the myeloma specialists who generously share their knowledge and expertise in the Beacon's myeloma discussion forum.

And the responses from the Advisors were surprising.

Surprising, because they were so similar.

The three Advisors who responded to the Beacon's question indepen­dently picked the same "hidden gem" -- specifically, the research presented at the meeting showing that …

Read the full story »

News»

[ by | Dec 16, 2011 2:24 pm | Comments Off ]
MLN9708,

The initial results from three early-phase clinical trials suggest that the investi­gational drug MLN9708, either alone or in combination with Revlimid and dexa­methasone, may be an effective treatment for both newly diagnosed multiple myeloma patients and patients with relapsed and/or treatment-resistant disease.

The findings from the three trials were presented earlier this week at the American Society of Hematology (ASH) annual meeting in San Diego.

MLN9708 (ixazomib) belongs to the same class of drugs as Velcade (bortezomib), called proteasome inhibitors, and it is being developed by Millennium Pharmaceuticals, the same company …

Read the full story »

News»

[ by | Dec 14, 2011 6:14 pm | 4 Comments ]
Elotuzumab Combination Effective For Relapsed And Refractory Multiple Myeloma (ASH 2011)

The most recent results of a Phase 2 clinical trial indicate that elotuzumab in combination with Revlimid and dexamethasone is safe and effective in relapsed and refractory multiple myeloma patients.

Dr. Sagar Lonial from the Winship Cancer Institute at the Emory University School of Medicine in Atlanta presented the updated Phase 2 results at the American Society for Hematology (ASH) annual meeting in San Diego on Monday.

The preceding Phase 1 trial of elotuzumab showed that 82 percent of relapsed/refractory myeloma patients had a partial response or better to the drug …

Read the full story »

News»

[ by | Dec 13, 2011 10:28 pm | 5 Comments ]
ASH 2011 Multiple Myeloma Update – Day Three Morning: Current Therapies

Yesterday, the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, was the busiest day of the meeting for people interested in multiple myeloma.  Myeloma-related presentations filled the entire morning and afternoon, and sometimes there were even multiple relevant presentations going on simultaneously.

The morning presentations about therapies combining current myeloma drugs will be covered in this update.  Morning presentations about potential new myeloma therapies were covered in an update published earlier today, and presentations from the rest of the day will be …

Read the full story »